TNSN05222A1 - Pharmaceutical composition comprising 5-methyl-2-2'-(chloro-6'-fluoroanilino) phenylacetic acid - Google Patents

Pharmaceutical composition comprising 5-methyl-2-2'-(chloro-6'-fluoroanilino) phenylacetic acid

Info

Publication number
TNSN05222A1
TNSN05222A1 TNP2005000222A TNSN05222A TNSN05222A1 TN SN05222 A1 TNSN05222 A1 TN SN05222A1 TN P2005000222 A TNP2005000222 A TN P2005000222A TN SN05222 A TNSN05222 A TN SN05222A TN SN05222 A1 TNSN05222 A1 TN SN05222A1
Authority
TN
Tunisia
Prior art keywords
fluoroanilino
chloro
methyl
pharmaceutical composition
phenylacetic acid
Prior art date
Application number
TNP2005000222A
Other languages
English (en)
Inventor
Patrick Forenzo
Maha Y Khaled
Barbara Wang
Joseph Lawrence Zielinski
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32990870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TNSN05222(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TNSN05222A1 publication Critical patent/TNSN05222A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
TNP2005000222A 2003-03-12 2005-09-09 Pharmaceutical composition comprising 5-methyl-2-2'-(chloro-6'-fluoroanilino) phenylacetic acid TNSN05222A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45414503P 2003-03-12 2003-03-12
PCT/EP2004/002528 WO2004080451A1 (en) 2003-03-12 2004-03-11 Pharmaceutical composition comprising 5-methyl-2-2’-(chloro-6’-fluoroanilino) phe nylacetic acid

Publications (1)

Publication Number Publication Date
TNSN05222A1 true TNSN05222A1 (en) 2007-06-11

Family

ID=32990870

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2005000222A TNSN05222A1 (en) 2003-03-12 2005-09-09 Pharmaceutical composition comprising 5-methyl-2-2'-(chloro-6'-fluoroanilino) phenylacetic acid

Country Status (30)

Country Link
US (2) US20060094787A1 (no)
EP (1) EP1603550B1 (no)
JP (1) JP4580921B2 (no)
KR (1) KR20050109077A (no)
CN (1) CN100345536C (no)
AR (1) AR043536A1 (no)
AT (1) ATE418332T1 (no)
AU (1) AU2004218921B2 (no)
BR (1) BRPI0408270A (no)
CA (1) CA2518393A1 (no)
CL (1) CL2004000496A1 (no)
DE (1) DE602004018622D1 (no)
EC (1) ECSP055998A (no)
ES (1) ES2318277T3 (no)
HK (1) HK1086492A1 (no)
HR (1) HRP20050787A2 (no)
IL (1) IL170518A (no)
IS (1) IS2658B (no)
MA (1) MA27670A1 (no)
MX (1) MXPA05009686A (no)
MY (1) MY139455A (no)
NO (1) NO20054662L (no)
NZ (1) NZ542218A (no)
PE (1) PE20041063A1 (no)
PT (1) PT1603550E (no)
RU (1) RU2363462C2 (no)
TN (1) TNSN05222A1 (no)
TW (1) TWI327913B (no)
WO (1) WO2004080451A1 (no)
ZA (1) ZA200506750B (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1673079A1 (en) * 2003-10-08 2006-06-28 Novartis AG Pharmaceutical composition comprising 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid
KR100900915B1 (ko) * 2007-05-07 2009-06-05 이연제약주식회사 메게스트롤 아세테이트를 함유하는 현탁액 제제 및 이의제조방법
US20100267787A1 (en) * 2007-11-12 2010-10-21 Gregory Harasymiw Pharmaceutical Compositions
EP2926810A1 (en) * 2014-03-31 2015-10-07 Sanovel Ilac Sanayi ve Ticaret A.S. Oral liquid pharmaceutical formulations of loxoprofen
WO2017218894A1 (en) * 2016-06-16 2017-12-21 Cutispharma, Inc. Composition and method for proton pump inhibitor suspension
CN109922801B (zh) * 2016-09-09 2023-07-18 库蒂斯制药公司 甲硝唑和巴氯芬的混悬剂和稀释剂
US11433074B2 (en) 2017-06-22 2022-09-06 Triact Therapeutics, Inc. Methods of treating glioblastoma
EP3687501A4 (en) 2017-09-29 2021-06-23 Triact Therapeutics, Inc. INIPARIB FORMS AND USES THEREOF
US11633478B2 (en) 2019-07-16 2023-04-25 Azurity Pharmaceuticals, Inc. Compositions and kits for Omeprazole suspension
US10751333B1 (en) 2019-07-16 2020-08-25 Cutispharma, Inc. Compositions and kits for omeprazole suspension

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112604A (en) * 1989-09-01 1992-05-12 Riker Laboratories, Inc. Oral suspension formulation
US5840768A (en) * 1997-06-04 1998-11-24 Fmc Corporation MCC: alginate pharmaceutical suspensions
US6103260A (en) * 1997-07-17 2000-08-15 Mcneil-Ppc, Inc. Simethicone/anhydrous calcium phosphate compositions
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
US20020028794A1 (en) * 2000-07-21 2002-03-07 Brubaker Greg Allen Megestrol acetate suspension
AR030630A1 (es) * 2000-09-11 2003-08-27 Novartis Ag Composiciones farmaceuticas
EP1469846A2 (en) * 2002-01-07 2004-10-27 Pharmacia Corporation Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin
CA2480832A1 (en) * 2002-04-05 2003-10-23 Nitromed, Inc. Nitric oxide donors, compositions and methods of use

Also Published As

Publication number Publication date
NO20054662L (no) 2005-12-05
CL2004000496A1 (es) 2005-01-14
RU2005131310A (ru) 2006-05-10
JP4580921B2 (ja) 2010-11-17
HK1086492A1 (en) 2006-09-22
EP1603550A1 (en) 2005-12-14
MXPA05009686A (es) 2005-10-20
AR043536A1 (es) 2005-08-03
DE602004018622D1 (de) 2009-02-05
US20090048344A1 (en) 2009-02-19
NZ542218A (en) 2009-01-31
MY139455A (en) 2009-10-30
AU2004218921A1 (en) 2004-09-23
CN100345536C (zh) 2007-10-31
MA27670A1 (fr) 2005-12-01
ATE418332T1 (de) 2009-01-15
IS8049A (is) 2005-09-28
NO20054662D0 (no) 2005-10-11
KR20050109077A (ko) 2005-11-17
PE20041063A1 (es) 2005-03-07
ECSP055998A (es) 2006-01-27
IS2658B (is) 2010-08-15
ES2318277T3 (es) 2009-05-01
BRPI0408270A (pt) 2006-03-07
IL170518A (en) 2010-11-30
PT1603550E (pt) 2009-03-20
WO2004080451A1 (en) 2004-09-23
JP2006519811A (ja) 2006-08-31
TW200505429A (en) 2005-02-16
CN1756541A (zh) 2006-04-05
AU2004218921B2 (en) 2007-05-17
TWI327913B (en) 2010-08-01
CA2518393A1 (en) 2004-09-23
ZA200506750B (en) 2007-02-28
EP1603550B1 (en) 2008-12-24
US20060094787A1 (en) 2006-05-04
HRP20050787A2 (en) 2006-12-31
RU2363462C2 (ru) 2009-08-10

Similar Documents

Publication Publication Date Title
TNSN05222A1 (en) Pharmaceutical composition comprising 5-methyl-2-2'-(chloro-6'-fluoroanilino) phenylacetic acid
ES2187300A1 (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.
IL161290A0 (en) Stable composition comprising particles in a frozen aqueous matrix
IL145430A0 (en) N-cyanomethyl amides, processes for the preparation thereof and pharmaceutical compositions containing the same
HK1076605A1 (en) Formulations
HU228253B1 (en) Substituted cyclohexane-1,4-diamine derivatives, process for their preparation and pharmaceutical compositions containing them
HRP20031003A2 (en) 4'-substituted nukleosides
IL163831A (en) Derivatives of aminoindazoles, pharmaceutical compositions comprising them, process for their preparation and use thereof
IL181700A0 (en) Quinazoline derivatives and pharmaceutical compositions containing the same
WO2004009549A3 (en) Piperidines useful for the treatment of central nervous system disorders
BRPI0008228B8 (pt) composição farmacêutica contendo n-benzoil estaurosporina e agentes solubilizantes
TW200509907A (en) Indol-6-yl sulfonamide derivatives, their preparation and their use in medicaments
EA200401515A1 (ru) Новые фармацевтические композиции, содержащие флибансерин в полиморфной модификации а
MY140630A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
TW200504029A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
TW200504030A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
TNSN04034A1 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
HRP20050603A2 (en) Novel anticonvulsant derivative salts
MY142076A (en) Emulsifying systems containing azetidine derivatives
HUP0402093A3 (en) 3-phenyl-2-phenethylthio-propionic acid derivatives as selective agonists of ppar-alpha, their preparation and pharmaceutical compositions containing them
MY139613A (en) Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders
WO2004113305A3 (en) Diamino substituted quinazoline derivatives as promoters of smn2
WO2004072037A8 (en) 2,3'-bipyridines derivatives as selective cox-2 inhibitors
MXPA06000483A (es) Sistemas semi-solidos que contienen derivados de azetidina.
AU2002364804A8 (en) Use of l isomers of amino acid derivatives of hydroxyguanidine for producing no, pharmaceutical compositions containing same and pharmaceutical uses